https://www.openbell.ai/ 2026-10-05T12:31:52.324Z hourly 1.0 https://www.openbell.ai/support 2026-10-05T12:31:52.324Z monthly 0.7 https://www.openbell.ai/privacy 2026-10-05T12:31:52.324Z monthly 0.5 https://www.openbell.ai/terms 2026-10-05T12:31:52.324Z monthly 0.5 https://www.openbell.ai/feed.json 2026-10-05T12:31:52.324Z hourly 0.8 https://www.openbell.ai/news/CRML:1791203473770 2026-10-05T12:31:13.770Z daily 0.9 https://cdn.brandfetch.io/CRML/w/400/h/400?c=1idopYfmtR7ZKg8QMud Critical Metals Receives Greenland Approval For Its Mining, Closure Plans For Its Tanbreez Project Critical Metals Corp. (Nasdaq: CRML) has received formal approval from the Government of Greenland for its Mining Plan and Closure Plan for the Tanbreez Project, which is recognized as one of the largest heavy rare earth deposits globally. This approval follows the exploitation licence granted in 2020 and outlines the operational and rehabilitation plans for the mine through 2050. https://www.openbell.ai/news/MELI:1791203311078 2026-10-05T12:28:31.078Z daily 0.9 https://cdn.brandfetch.io/MELI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Why Is MercadoLibre Stock Surging Monday? MercadoLibre, Inc. (NASDAQ: MELI) saw its stock rise approximately 6% in premarket trading following Brazil's first-round presidential election, which appears to favor far-right candidate Flavio Bolsonaro, known for advocating fiscal discipline. Brazil is crucial for MercadoLibre, contributing $15.2 billion of its $28.9 billion in net revenues for 2025, making it the company's largest market. Additionally, MercadoLibre plans to invest $10.9 billion in Brazil in 2026 to enhance logistics and marketplace operations. The stock is currently trading around $1,791.20, up 5.58% in premarket activity. https://www.openbell.ai/news/MELI:1791203275931 2026-10-05T12:27:55.931Z daily 0.9 https://cdn.brandfetch.io/MELI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Why Is MercadoLibre Stock Surging Monday? MercadoLibre, Inc. (NASDAQ: MELI) saw its stock rise approximately 6% in premarket trading following Brazil's first-round presidential election, which appears to favor far-right candidate Flavio Bolsonaro, known for advocating fiscal discipline. Brazil accounted for about 52.6% of MercadoLibre's $28.9 billion net revenues in 2025, making its economic outlook crucial for the company's performance. Additionally, MercadoLibre plans to invest $10.9 billion in Brazil in 2026, aimed at expanding logistics and enhancing its marketplace. The stock is currently trading at $1,791.20, up 5.58% during the premarket session. https://www.openbell.ai/news/MELI:1791203264716 2026-10-05T12:27:44.716Z daily 0.9 https://cdn.brandfetch.io/MELI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Why Is MercadoLibre Stock Surging Monday? MercadoLibre, Inc. (NASDAQ: MELI) stock rose approximately 6% during Monday's premarket session, driven by favorable market reactions to Brazil's first-round presidential election, particularly towards far-right candidate Flavio Bolsonaro. Brazil is crucial for MercadoLibre, generating $15.2 billion of its $28.9 billion in net revenues for 2025, accounting for about 52.6% of total revenues. The company also announced a $10.9 billion investment plan in Brazil for 2026, aimed at expanding logistics and improving its marketplace. Analysts expect the upcoming quarterly earnings report on October 28 to show earnings of $9.49 per share and revenue of $10.27 billion, reflecting significant growth from the previous year. https://www.openbell.ai/news/MELI:1791203237346 2026-10-05T12:27:17.346Z daily 0.9 https://cdn.brandfetch.io/MELI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Why Is MercadoLibre Stock Surging Monday? MercadoLibre, Inc. (NASDAQ: MELI) stock surged approximately 6% in premarket trading following Brazil's first-round presidential election, where far-right candidate Flavio Bolsonaro is favored for his promises of fiscal discipline. Brazil is crucial for MercadoLibre, contributing $15.2 billion of its $28.9 billion in net revenues in 2025, making it the company's largest market. The company plans to invest $10.9 billion in Brazil in 2026 to expand logistics and improve its marketplace. Currently, the stock is trading at $1,791.20, up 5.58% during the premarket session. https://www.openbell.ai/news/HLSQ:1791203192485 2026-10-05T12:26:32.485Z daily 0.9 https://cdn.brandfetch.io/HLSQ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Zorronet Signs Joint Framework Agreement With Team-Netcom Zorronet has signed a joint framework agreement with Team-Netcom Ltd., where Team-Netcom will act as the prime contractor and systems integrator for project delivery and customer implementation. Zorronet will contribute its AI intelligence layer to enhance the integration of cameras, sensors, and other security systems, enabling real-time activity understanding and event validation. The technology will also facilitate object detection and classification across various scenarios, including security and safety. https://www.openbell.ai/news/AMD:1791203148319 2026-10-05T12:25:48.319Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/05/Jakarta-May-02-2024-Advanced-Micro-Devic.jpg?width=250&height=187 AMD To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Monday Stifel has raised the price target for Advanced Micro Devices Inc (AMD) from $635 to $700, maintaining a Buy rating, while AMD shares closed at $633.91 on Friday. This adjustment comes amid a broader analysis of various stocks by top Wall Street analysts, with AMD potentially set to rally more than 10%. Other notable changes include price target adjustments for ON Semiconductor Corp and Generac Holdings Inc, reflecting varied analyst sentiments across the market. https://www.openbell.ai/news/MELI:1791203026133 2026-10-05T12:23:46.133Z daily 0.9 https://cdn.brandfetch.io/MELI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Why Is MercadoLibre Stock Surging Monday? MercadoLibre, Inc. (NASDAQ: MELI) stock surged approximately 6% in premarket trading on Monday, influenced by favorable polling for far-right candidate Flavio Bolsonaro in Brazil's presidential election, which is seen as beneficial for fiscal discipline. Brazil is crucial for MercadoLibre, contributing $15.2 billion of its $28.9 billion in net revenues for 2025, making it the company's largest market. The company plans to invest about $10.9 billion in Brazil in 2026, focusing on logistics and marketplace improvements. Currently, the stock is trading at $1,791.20, reflecting a 5.58% increase during the premarket session. https://www.openbell.ai/news/MELI:1791203011093 2026-10-05T12:23:31.093Z daily 0.9 https://cdn.brandfetch.io/MELI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Why Is MercadoLibre Stock Surging Monday? MercadoLibre, Inc. (NASDAQ: MELI) stock surged approximately 6% in premarket trading on Monday, influenced by favorable polling for far-right candidate Flavio Bolsonaro in Brazil's presidential election, which is seen as beneficial for fiscal discipline. Brazil accounted for $15.2 billion of MercadoLibre's $28.9 billion in net revenue in 2025, making it the company's largest market. Additionally, MercadoLibre plans to invest about $10.9 billion in Brazil in 2026, aimed at expanding logistics and improving its marketplace. The stock was trading at $1,791.20 during the premarket session, reflecting a 5.58% increase. https://www.openbell.ai/news/MELI:1791202996355 2026-10-05T12:23:16.355Z daily 0.9 https://cdn.brandfetch.io/MELI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Why Is MercadoLibre Stock Surging Monday? MercadoLibre, Inc. (NASDAQ: MELI) stock surged approximately 6% during Monday's premarket session, influenced by favorable polling for far-right presidential candidate Flavio Bolsonaro in Brazil, which is crucial for the company's operations. Brazil accounted for $15.2 billion of MercadoLibre's $28.9 billion in net revenues in 2025, making it the largest market for the company. Additionally, MercadoLibre announced a $10.9 billion investment plan in Brazil for 2026, aimed at expanding logistics and enhancing its marketplace. The stock was trading at $1,791.20, reflecting a 5.58% increase in premarket activity. https://www.openbell.ai/news/EZRA:1791202982108 2026-10-05T12:23:02.108Z daily 0.9 https://cdn.brandfetch.io/EZRA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Reliance Global Group Repays In Full Its ~$4.4M Term Loan With Oak Street Funding, Co. Has No Outstanding Term Debt Reliance Global Group, Inc. (NASDAQ: EZRA) has fully repaid its term loan of approximately $4.4 million with Oak Street Funding, eliminating its only term debt. The repayment was funded through proceeds from the sale of Southwestern Montana Insurance Center and Altruis Benefit Consulting, along with cash previously held as collateral. Following the repayment, Reliance has over $6 million in cash on its balance sheet. https://www.openbell.ai/news/LFST:1791202894586 2026-10-05T12:21:34.586Z daily 0.9 https://cdn.brandfetch.io/LFST/w/400/h/400?c=1idopYfmtR7ZKg8QMud Keybanc Maintains Overweight on LifeStance Health Gr, Raises Price Target to $15 Keybanc analyst Steve Dechert has maintained an Overweight rating on LifeStance Health Group (NASDAQ: LFST) and raised the price target from $13 to $15. This adjustment reflects a positive outlook on the company's performance. https://www.openbell.ai/news/CRM:1791202832614 2026-10-05T12:20:32.614Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/05/Overjoyed-Diverse-Coworkers-Celebrating-.jpg?width=250&height=187 Top Economist Warns AI Could Triple Unemployment Within a Decade — ‘What We Are Living Through…Is Unprecedented’ Nobel Prize-winning economist Daron Acemoglu warns that AI could triple unemployment within a decade if no changes are made, highlighting the unprecedented speed of AI-driven job disruption compared to past technological shifts. A Pew Research study indicates that nearly 75% of Americans fear job loss due to AI, while a McKinsey report suggests AI may push 11 million U.S. workers into new careers by 2035. Conversely, some industry leaders, like Mercor CEO Brendan Foody, view AI as a natural evolution that could create new high-paying jobs in AI training. https://www.openbell.ai/news/ANIX:1791202695606 2026-10-05T12:18:15.606Z daily 0.9 https://cdn.brandfetch.io/ANIX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Anixa Biosciences Participant In Its Current Phase 1 Study Of FSHR-Targeted CAR-T Therapy For Recurrant Ovarian Cancer Demonstrates Stable Disease After 90 Days Of Treatment; Patient Was Treated In Fifth Dose Cohort Anixa Biosciences, Inc. (NASDAQ: ANIX) reported that a patient in its Phase 1 clinical trial for FSHR-targeted CAR-T therapy for recurrent ovarian cancer showed stable disease after 90 days of treatment. This marks the first positive response in the trial, with the patient receiving the highest dose level of 1×10⁷ CAR-positive cells per kilogram. No dose-limiting toxicities have been observed in the study thus far, and correlative studies on CAR positive cells are ongoing. https://www.openbell.ai/news/TSM:1791202648916 2026-10-05T12:17:28.916Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/05/TSMC--Photo-by-Sundry-Photography-on-Shu.jpg?width=250&height=187 Taiwan Semiconductor Stock Hits 52-Week High — What's Going On? Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE: TSM) has reached a new 52-week high, with shares up nearly 60% in 2026 due to increasing demand for AI semiconductors. The company is exploring a potential multi-billion dollar manufacturing campus in Texas, with each fabrication plant estimated to cost at least $20 billion. In the second quarter, TSM reported a 34% year-over-year revenue increase to $40.2 billion, and analysts expect full-year 2026 revenue to grow by about 43%. TSM is scheduled to report earnings on October 15, with expectations of $4.45 per share and $45.54 billion in revenue. https://www.openbell.ai/news/WULF:1791202586232 2026-10-05T12:16:26.232Z daily 0.9 https://cdn.brandfetch.io/WULF/w/400/h/400?c=1idopYfmtR7ZKg8QMud TeraWulf Expands Contracted Power Capacity With Kentucky Power. openbell Financial News https://www.openbell.ai/news/NTR:1791202560668 2026-10-05T12:16:00.668Z daily 0.9 https://cdn.brandfetch.io/NTR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Nutrien Plans To Indefinitely Shut Down Its Trinidad Nitrogen Business At Point Lisas Site Nutrien Ltd. (TSX and NYSE: NTR) has announced the indefinite shutdown of its Trinidad Nitrogen operations at the Point Lisas Facility due to ongoing natural gas constraints and uncertainty. This decision follows a controlled shutdown initiated on October 23, 2025, aimed at addressing port access restrictions and unreliable natural gas supply, which had negatively impacted free cash flow. The company believes this move will enhance free cash flow and return on invested capital. https://www.openbell.ai/news/RS:1791202547349 2026-10-05T12:15:47.349Z daily 0.9 https://cdn.brandfetch.io/RS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Keybanc Maintains Overweight on Reliance, Raises Price Target to $421 Keybanc analyst Samuel McKinney has maintained an Overweight rating on Reliance (NYSE: RS) and increased the price target from $418 to $421. This adjustment reflects a positive outlook for the company's stock performance. https://www.openbell.ai/news/ZS:1791202235011 2026-10-05T12:10:35.011Z daily 0.9 https://cdn.brandfetch.io/ZS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Zscaler, IBM And Red Hat Collaborate To Protect Private Applications openbell Financial News https://www.openbell.ai/news/NVDA:1791202190379 2026-10-05T12:09:50.379Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/05/Jensen-Huang-Nvidias-Founder--President-.jpg?width=250&height=187 Nvidia, Okta, Cognex And An Industrial Stock On CNBC’s ‘Final Trades’ On CNBC's 'Halftime Report Final Trades', Bryn Talkington expressed optimism for Nvidia Corporation (NASDAQ: NVDA), supported by Cantor Fitzgerald's Overweight rating and a $350 price target. Nvidia recently announced a record $150 billion share buyback program, in addition to an existing $80 billion plan. Other stocks discussed included Okta, which received an upgraded price target from Morgan Stanley, Cognex, which is acquiring RealSense for $500 million, and Delta Air Lines, expected to report earnings of $1.88 per share on revenue of $18.83 billion. https://www.openbell.ai/news/VTVT:1791202187836 2026-10-05T12:09:47.836Z daily 0.9 https://cdn.brandfetch.io/VTVT/w/400/h/400?c=1idopYfmtR7ZKg8QMud vTv Therapeutics Completes Enrollment In Its Phase 3 Cadisegliatin As Adjunctive Therapy In Type 1 Diabetes Trial vTv Therapeutics Inc. has completed enrollment for its Phase 3 Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes (CATT1) study, involving 166 randomized patients. The study evaluates cadisegliatin, a novel oral therapy that has received Breakthrough Therapy designation from the FDA, aimed at being a first-in-class liver-selective glucokinase activator for T1D treatment. https://www.openbell.ai/news/AVBC:1791202168871 2026-10-05T12:09:28.871Z daily 0.9 https://cdn.brandfetch.io/AVBC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Hovde Group Initiates Coverage On Avidia Bancorp with Outperform Rating, Announces Price Target of $26 Hovde Group has initiated coverage on Avidia Bancorp (NYSE: AVBC) with an Outperform rating. The firm has set a price target of $26 for the company's stock. https://www.openbell.ai/news/RANI:1791202147347 2026-10-05T12:09:07.347Z daily 0.9 https://cdn.brandfetch.io/RANI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Rani Therapeutics Joins FDA Emerging Technology Platform Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) has announced that its RaniPill® Capsule platform technology has been accepted into the FDA's Emerging Technology Program (ETP). This acceptance marks a significant step for the clinical-stage biotherapeutics company, which specializes in the oral delivery of biologics. https://www.openbell.ai/news/RADX:1791202143139 2026-10-05T12:09:03.139Z daily 0.9 https://cdn.brandfetch.io/RADX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Radiopharm Theranostics Announces Completion Of EOP2 Meeting With FDA Regarding RAD101, Investigational Radiopharmaceutical Imaging Agent For Detection Of Brain Metastases Radiopharm Theranostics Limited has successfully completed an End-of-Phase 2 meeting with the FDA regarding RAD101, an investigational radiopharmaceutical imaging agent for detecting brain metastases. The company is currently engaged in Phase 3 readiness activities and expects to receive official FDA meeting minutes within the next 30 days, which will outline the Agency's feedback on the pivotal clinical development plan. RAD101 has shown a 93% concordance with MRI in previous Phase 2b trials, meeting its primary endpoint. https://www.openbell.ai/news/PRME:1791202140950 2026-10-05T12:09:00.950Z daily 0.9 https://cdn.brandfetch.io/PRME/w/400/h/400?c=1idopYfmtR7ZKg8QMud Prime Medicine Announces First Patient Dosed In Phase 1/2 Trial Of PM577a In Wilson Disease; Receives FDA Rare Pediatric Disease Designation openbell Financial News https://www.openbell.ai/news/PCRX:1791202101625 2026-10-05T12:08:21.625Z daily 0.9 https://cdn.brandfetch.io/PCRX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Pacira BioSciences Announces Exclusive Agreement With Molteni Farmaceutici To Commercialize EXPAREL In Europe; Pacira To Receive Undisclosed Upfront Payment Plus Royalties openbell Financial News https://www.openbell.ai/news/KTOS:1791202070479 2026-10-05T12:07:50.479Z daily 0.9 https://cdn.brandfetch.io/KTOS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Kratos Defense & Security Solutions Announces Multiple Contract Awards Worth $100M+ For Prototype Mission Applications And Cyber Capabilities Kratos Defense & Security Solutions has secured multiple contracts exceeding $100 million to develop prototype mission applications and cyber capabilities for warfighters. These contracts will enhance electronic warfare and offensive cyber operations, utilizing Kratos' KnownSpace® Network, which includes over 190 global RF sensors. The projects aim to improve capabilities in collecting and processing complex RF signals and support the joint targeting cycle, leveraging Kratos' extensive experience in RF, signal processing, and cybersecurity. https://www.openbell.ai/news/LSTA:1791202040485 2026-10-05T12:07:20.485Z daily 0.9 https://cdn.brandfetch.io/LSTA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Lisata’s Marea Therapeutics Announces First Patient Dosed In Its Phase 2 Clinical Trial Of MAR002 For Treatment Of Acromegaly Marea Therapeutics, a subsidiary of Lisata Therapeutics, has announced the dosing of the first patient in its Phase 2 clinical trial for MAR002, aimed at treating acromegaly. This investigational therapy, a first-in-class allosteric monoclonal antibody, has shown promising results in a Phase 1 trial, demonstrating deep and durable IGF-1 suppression with potential for biweekly dosing, unlike the current daily injections. Acromegaly is a chronic disorder caused by excess growth hormone, leading to serious health complications if untreated. https://www.openbell.ai/news/RZLV:1791201994645 2026-10-05T12:06:34.645Z daily 0.9 https://cdn.brandfetch.io/RZLV/w/400/h/400?c=1idopYfmtR7ZKg8QMud Rezolve Ai Inks Reseller Deal With Mastercard To Create a New Distribution Channel For Rezolve Ai’s Technology As Business Prepare For AI-Driven Commerce Rezolve Ai (NASDAQ: RZLV) has entered into a worldwide reseller agreement with Mastercard to create a new distribution channel for its AI-powered commerce technology. Under this agreement, Mastercard will market and sell subscriptions to Rezolve Ai’s software and SaaS services on a non-exclusive basis, coordinating the sales process and contracting directly with resale customers. https://www.openbell.ai/news/AMPX:1791201963239 2026-10-05T12:06:03.239Z daily 0.9 https://cdn.brandfetch.io/AMPX/w/400/h/400?c=1idopYfmtR7ZKg8QMud CAMINUS Announces Contract Manufacturing Agreement With Amprius Technologies CAMINUS has entered into a contract manufacturing agreement with Amprius Technologies to produce silicon-anode pouch cells at its Indianapolis facility. This agreement will enhance domestic production capacity for Amprius's customers in sectors such as aviation, defense, and uncrewed systems. CAMINUS, formerly known as EnPower, specializes in lithium-ion battery cells and electrodes. https://www.openbell.ai/news/XP:1791201940008 2026-10-05T12:05:40.008Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_2.jpg?width=250&height=187 11 Financials Stocks Moving In Monday's Pre-Market Session In Monday's pre-market session, XP (NASDAQ: XP) shares rose by 17.2% to $25.2, with a market capitalization of $10.9 billion. Other notable gainers included StoneCo (NASDAQ: STNE), which increased by 16.33% to $11.11, and PagSeguro Digital (NYSE: PAGS), up 16.24% to $10.48. Conversely, Triller Group (NASDAQ: ILLR) saw a decline of 8.0% to $0.23, with a market value of $5.0 million. https://www.openbell.ai/news/AIFA:1791201939804 2026-10-05T12:05:39.804Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=250&height=187 12 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session In Monday's pre-market session, All In FutureTech (NASDAQ:AIFA) saw a significant stock increase of 14.8%, reaching $5.13, with a market value of $28.6 million. Other notable gainers included LightInTheBox Holding (NYSE:LITB), which rose 14.23% to $3.21, and Ultrapar Participacoes (NYSE:UGP), up 12.75% to $8.4, with a market cap of $7.9 billion. Conversely, Zeta Network Group (NASDAQ:ZNB) experienced the largest decline, falling 20.8% to $1.22, while Leslies (NASDAQ:LESL) dropped 17.71% to $0.12, with a market value of $1.3 million. https://www.openbell.ai/news/APUS:1791201939611 2026-10-05T12:05:39.611Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_1.jpg?width=250&height=187 12 Health Care Stocks Moving In Monday's Pre-Market Session In Monday's pre-market session, Apimeds Pharmaceuticals (AMEX: APUS) saw a significant increase of 76.7%, reaching $5.69, with a market value of $4.8 million. Other notable gainers included Alector (NASDAQ: ALEC), which rose 56.9% to $2.84, and Vaxcyte (NASDAQ: PCVX), which increased by 54.92% to $87.5, with a market cap of $8.4 billion. Conversely, Sunshine Biopharma (NASDAQ: SBFM) experienced a decline of 20.5%, falling to $0.53, while Pomdoctor (NASDAQ: POM) dropped 18.42% to $0.70. https://www.openbell.ai/news/RXO:1791201939358 2026-10-05T12:05:39.358Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=250&height=187 12 Industrials Stocks Moving In Monday's Pre-Market Session In Monday's pre-market session, RXO's stock rose by 21.0% to $28.3, with a market value of $3.8 billion. Other notable gainers included Cheetah Net Supply Chain, which increased by 12.58% to $2.95, and SVRN, which rose by 12.47% to $40.67. Conversely, Flux Power Holdings saw a significant decline of 19.4% to $0.52, while C.H. Robinson Worldwide's stock fell by 10.75% to $140.77. https://www.openbell.ai/news/DFDV:1791201900104 2026-10-05T12:05:00.104Z daily 0.9 https://cdn.brandfetch.io/DFDV/w/400/h/400?c=1idopYfmtR7ZKg8QMud DeFi Development Says It Holds About 2,564,212 SOL Worth $302M After Adding 26,203; Expects NAV Per Share Up More Than 100% Since August 12 openbell Financial News https://www.openbell.ai/news/NTRA:1791201893036 2026-10-05T12:04:53.036Z daily 0.9 https://cdn.brandfetch.io/NTRA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Alliance Foundation Trials And Natera Launch AFT-70 NAVIGATE, Randomized Phase III Trial Evaluating MRD-Guided Treatment Strategy For Patients With Intermediate And High-Risk ER-Positive/HER2-Negative Early Breast Cancer Alliance Foundation Trials and Natera have launched the AFT-70 NAVIGATE, a randomized Phase III trial to evaluate a molecular residual disease (MRD)-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cancer. The trial will utilize Natera's ultrasensitive MRD test, Signatera, in conjunction with Genentech's investigational oral SERD, giredestrant, to minimize unnecessary exposure to CDK4/6 inhibitors. The trial is sponsored by AFT with collaboration and co-funding from Natera and Genentech. https://www.openbell.ai/news/APUS:1791201833165 2026-10-05T12:03:53.165Z daily 0.9 https://cdn.brandfetch.io/APUS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Apimeds' MindWave Announces 2-Year Contract To Build, Run Insurance Blockchain For BlockAssure, With 20% Of Planned Token Supply; Fees Not Disclosed openbell Financial News https://www.openbell.ai/news/OPTX:1791201831512 2026-10-05T12:03:51.512Z daily 0.9 https://cdn.brandfetch.io/OPTX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Syntec Optics Receives Recurring Production Orders For Actuators In NASA's Artemis III Rockets Syntec Optics Holdings, Inc. (Nasdaq: OPTX) has announced recurring production orders for actuators used in NASA's Artemis III rockets. The company specializes in providing ultra-precise products essential for maintaining the trajectory of rockets. This development highlights Syntec Optics' role in the defense and space sectors. https://www.openbell.ai/news/GANX:1791201827806 2026-10-05T12:03:47.806Z daily 0.9 https://cdn.brandfetch.io/GANX/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Gain Therapeutics (NASDAQ: GANX) and maintained a price target of $8 for the stock. https://www.openbell.ai/news/COYA:1791201821593 2026-10-05T12:03:41.593Z daily 0.9 https://cdn.brandfetch.io/COYA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Coya Therapeutics Announces Full Enrollment Of Planned 120 Participants In Phase 2/3 ALSTARS Trial Evaluating COYA 302 For Potential Treatment Of Amyotrophic Lateral Sclerosis Coya Therapeutics has successfully enrolled the planned 120 participants in its Phase 2/3 ALSTARS Trial, which is evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS). Additional eligible participants in active screening may also enroll. The company expects to release topline data from the 24-week double-blind treatment phase in early Q2 2027. https://www.openbell.ai/news/SEVN:1791201776851 2026-10-05T12:02:56.851Z daily 0.9 https://cdn.brandfetch.io/SEVN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Seven Hills Realty Trust Says It Closed $98M In New Loans; Office Exposure Falls To 13% From 19% openbell Financial News https://www.openbell.ai/news/FRMM:1791201766249 2026-10-05T12:02:46.249Z daily 0.9 https://cdn.brandfetch.io/FRMM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Forum Markets Creates Forum Edge AI Joint Venture With Edge Node Forum Markets, Incorporated (Nasdaq: FRMM) has established a joint venture, Forum Edge AI LLC, with Edge Node Inc. to enhance its AI infrastructure capabilities. The venture, formed on October 2, 2026, will manage high-performance inference compute capacity, beginning with a portfolio that includes a 4 MW data center in Dallas and a 9 MW data center campus in High Point, N.C. Forum holds majority ownership of the joint venture and plans to expand its operations by contracting additional sites with other communications tower owners. https://www.openbell.ai/news/RVMD:1791201734166 2026-10-05T12:02:14.166Z daily 0.9 https://cdn.brandfetch.io/RVMD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Revolution Medicines Begins Treating Patients In RASolute 309, Global, Randomized Phase 3 Clinical Trial Evaluating Combination Of RASONQUE And Zoldonrasib As First-Line Treatment In Adult Patients With Metastatic RAS G12D PDAC Revolution Medicines, Inc. (NASDAQ: RVMD) has initiated patient treatment in the RASolute 309 clinical trial, which is a global, randomized Phase 3 study. This trial is assessing the efficacy of the combination of RASONQUE (daraxonrasib) and zoldonrasib as a first-line treatment for adult patients with metastatic RAS G12D pancreatic adenocarcinoma (PDAC). https://www.openbell.ai/news/SGP:1791201701066 2026-10-05T12:01:41.066Z daily 0.9 https://cdn.brandfetch.io/SGP/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on SpyGlass Pharma (NASDAQ: SGP) and maintained a price target of $37 for the stock. https://www.openbell.ai/news/ESTA:1791201696643 2026-10-05T12:01:36.643Z daily 0.9 https://cdn.brandfetch.io/ESTA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Establishment Labs Says FDA Approved 28 New Sizes Of Motiva Breast Implants, Available Before Year-End openbell Financial News https://www.openbell.ai/news/PUSA:1791201686788 2026-10-05T12:01:26.788Z daily 0.9 https://cdn.brandfetch.io/PUSA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Powerus Receives $82M Order For Counter-Unmanned Aerial Systems Powerus Corporation (Nasdaq: PUSA) has received an $82 million order for counter-unmanned aerial systems under an existing U.S. government indefinite-delivery/indefinite-quantity (IDIQ) contract. This marks the second order placed under this contract, with deliveries anticipated over the next several quarters. https://www.openbell.ai/news/TELA:1791201651596 2026-10-05T12:00:51.596Z daily 0.9 https://cdn.brandfetch.io/TELA/w/400/h/400?c=1idopYfmtR7ZKg8QMud TELA Bio Says FDA Cleared Liora Resorbable Surgical Mesh For Soft Tissue Reinforcement openbell Financial News https://www.openbell.ai/news/MLTX:1791201593181 2026-10-05T11:59:53.181Z daily 0.9 https://cdn.brandfetch.io/MLTX/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $50 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on MoonLake (NASDAQ: MLTX) and maintained a price target of $50 for the stock. https://www.openbell.ai/news/BND:1791201563372 2026-10-05T11:59:23.372Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/05/A-Risk-For-US-Government-Bonds-And-The-D.jpg?width=250&height=187 ‘Preserve and Protect’: Why the ‘Bond King’ Is Avoiding His Own Asset Class Bill Gross, known as the 'Bond King', has advised investors to avoid bonds, citing a dangerously unbalanced credit landscape with net federal debt at approximately 100% of GDP. He recommends one-year Treasury bills at 4.55% as a safer option, while warning of increased volatility in the bond market, particularly with the 10-year Treasury yield reaching 5.34%, the highest in 24 years. Gross also notes that traditional buyers of long-dated Treasuries are retreating, with significant shifts towards private credit, as Japan reduces its holdings of foreign bonds. https://www.openbell.ai/news/PWR:1791201524855 2026-10-05T11:58:44.855Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/05/Jim-Cramer-At-The-Cable-Show-2010-An-Eve.jpg?width=250&height=187 Jim Cramer: This 'Terrific' Industrial Stock Is 'Done Going Down' Jim Cramer recommended buying Quanta Services, Inc. (NYSE: PWR), noting a potential increase in building activity post-election. Bernstein analyst Chad Dillard upgraded the stock from Market Perform to Outperform, raising the price target from $748 to $775. Additionally, Planet Labs PBC (NYSE: PL) saw an 8.4% increase in shares after launching 20 satellites, while Duke Energy Corporation (NYSE: DUK) declared a quarterly cash dividend of $1.08 per share.